Lilly claims that the weight loss drug Mounjaro has been approved for sale in Hong Kong
海角七号
发表于 昨天 10:08
119
0
0
On October 28, Lilly said in a statement that it had obtained the approval of the Hong Kong SAR government to sell its Tirzepatide injection (trade name: Mounjaro) through a device called Kwikpen (pre filled injection pen) for long-term weight management and type 2 diabetes. Lilly is expected to start selling this weight loss medication in Hong Kong as early as the end of this year. (Bloomberg)
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Lilly diabetes drug is approved for adult weight loss in the United States, and its price is 20% cheaper than that of Pinot Noir and Nordisk
- Sanofi: Expected to contribute over 10 billion euros in newly launched innovative drugs by 2030
- AstraZeneca elontersen approved in the United States
- Novo Nordisk plans to introduce weight loss oral small molecule drugs for 235 million euros
- Approval of new indications for Mercado Pembrolizumab
- AstraZeneca IL-5R α monoclonal antibody approved for market in China
- AstraZeneca and Sinopharm Group reach nearly $2 billion cardiovascular drug authorization agreement
- Johnson&Johnson's drug Zebaike has been approved in China
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
-
(记者韦博雅)10月25日,英特尔在北京举办酷睿Ultra 200V移动处理器品鉴会以及酷睿Ultra 200S台式机处理器发布会。会上,英特尔客户端计算事业部副总裁冯大为表示,AI是无线互联网以来推动端侧发展的最强驱动力 ...
- wrq
- 前天 17:09
- 支持
- 反对
- 回复
- 收藏
-
美国当地时间10月25日,阿里巴巴集团发布公告,已同意支付4.335亿美元(约合30.87亿元人民币)和解投资者在美国提起的一桩集体诉讼。 该诉讼案指控阿里巴巴存在垄断行为,但阿里巴巴否认其存在任何不当行为 ...
- 1234ljx
- 前天 10:00
- 支持
- 反对
- 回复
- 收藏
-
【波音发行9000万股股票和50亿美元存托股票】波音公司10月28日宣布启动公开发售:90,000,000股每股面值5.00美元的普通股;50亿美元的存托股票。波音打算将募集资金净额用于一般公司用途,其中可能包括偿还债务、增加 ...
- 天天精品
- 昨天 19:33
- 支持
- 反对
- 回复
- 收藏
-
证券时报e公司讯,10月28日,英特尔宣布扩容英特尔成都封装测试基地。在现有的客户端产品封装测试的基础上,增加为服务器芯片提供封装测试服务,并设立一个客户解决方案中心,以提高本土供应链的效率,加大对中 ...
- jiliang
- 昨天 11:48
- 支持
- 反对
- 回复
- 收藏